Biodesix Inc (BDSX): Capital Expenditures
$259.0K
Year ended 2025-12-31
$412.0K
Trailing 12 months to 2026-06-30
-57.2%
3-year compound annual growth
-33.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $259.0K | -92.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $3.23M | -85.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $22.92M | +594.9% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $3.30M | +47.2% | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | $2.24M | +15.2% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $1.95M | +48.5% | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | $1.31M | n/a | 2021-03-16, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Biodesix Inc (BDSX) | 2025-12-31 | $259.0K | -92.0% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $4.50M | +181.0% |
| Exagen Inc. (XGN) | 2025-12-31 | $641.0K | +24.5% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $909.0K | -82.5% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $7.63M | -3.8% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $8.88M | +64.4% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $22.57M | -44.0% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $36.02M | +27.2% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $9.68M | -14.3% |
Compare BDSX, PSNL, XGN, GRAL side by side · Screen every company in Services-Medical Laboratories ↗